Sarepta Therapeutics (SRPT) Posts Wider Q4 Loss; NDA Submission for Eteplirsen Planned for Mid-Year 2015

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. USO
8. HOOD
9. DFTX
10. IBM

Go back to Sarepta Therapeutics (SRPT) Posts Wider Q4 Loss; NDA Submission for Eteplirsen Planned for Mid-Year 2015

Sarepta Therapeutic (SRPT) PT Cut to $38 at Needham & Company; 'Buy' Maintained

March 2, 2015 8:43 AM EST

Needham & Company analyst Chad Messer cut his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $38.00 (from $52.00) but maintained a Buy rating following Q4 results and news the company remains on track to file an NDA for eteplirsen in Duchenne's muscular dystrophy (DMD) by... More

Cowen Downgrades Sarepta Therapeutic (SRPT) to Market Perform

February 27, 2015 9:15 AM EST

Cowen downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Outperform to Market Perform and removed its price target (prior $19.00).

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $13.82 yesterday.

... More

Baird Maintains Neutral View on Sarepta Therapeutic (SRPT) Post Q4

February 27, 2015 9:07 AM EST

Baird analyst Brian Skorney reiterated a Neutral rating and $16 price target on Sarepta Therapeutic (NASDAQ: SRPT) following Q4 results.

Skorney commented, "No change to outlook following 4Q14. We're remaining on the sidelines here after the 4Q14 update didn't give us enough... More